Pomerantz Law Firm Warns Investors About Hims & Hers Class Action Lawsuit and Deadlines

Overview of the Class Action Lawsuit Against Hims & Hers

Pomerantz LLP, a well-known law firm specializing in corporate, securities, and antitrust litigation, recently announced a class action lawsuit against Hims & Hers Health, Inc. (NYSE: HIMS) that has raised alarms among investors. If you are an investor who has experienced losses while holding shares in Hims & Hers, this article provides important information regarding your rights and the ongoing legal proceedings.

Details of the Lawsuit

The class action lawsuit stems from allegations that Hims & Hers, alongside certain individuals in leadership positions, has engaged in securities fraud and other unlawful business practices. Investors who acquired Hims & Hers securities during the specified Class Period have until August 25, 2025, to request to be appointed as Lead Plaintiff in this case. Interested parties are encouraged to contact Danielle Peyton at Pomerantz LLP, either by phone or email, including relevant personal information and the number of shares held for processing.

Recent Developments and Their Impact

The lawsuit follows a significant partnership announcement on April 29, 2025, where Hims & Hers revealed a collaboration with Novo Nordisk, allowing the sale of the FDA-approved drug Wegovy® through their platform. However, this partnership would meet an abrupt end on June 23, 2025, when Novo Nordisk accused Hims & Hers of misleading promotional activities surrounding a knockoff version of Wegovy®. This situation has raised major concerns regarding the safety and efficacy of Hims & Hers products, particularly around compounded drugs that are purportedly marketed as personalized medicine.

In their press release, Novo Nordisk reported findings indicating that the active pharmaceutical ingredients in the unauthorized drugs offered by Hims & Hers were sourced from foreign suppliers in China, specifically highlighting that these ingredients were not approved by the FDA and could pose significant risks to patient safety. Following this announcement, Hims & Hers' stock plummeted by over 34%, closing at $41.98 per share. This steep decline reflects investor panic amid fears of legal repercussions and damage to the company's reputation.

Pomerantz Law Firm’s Role

With a legacy spanning over 85 years, Pomerantz LLP has established itself as a formidable player in the area of securities class actions, pioneering this field with a commitment to seeking justice for investors. They have recovered numerous substantial damages awards for class members in previous litigations. The firm continues to advocate for the rights of those impacted by corporate misconduct, including breaches of fiduciary duty and securities fraud. Their dedication to fighting for victims of financial malpractice is at the core of their operations.

Next Steps for Investors

If you believe that you have suffered losses during the Class Period for Hims & Hers, it is crucial to take prompt action. Engage with Pomerantz LLP by reaching out for more information about joining the class action. The law firm advises that time-sensitive information will be critical to securing your position in this case, which seeks to hold Hims & Hers accountable for its alleged wrongdoing.

Conclusion

The ongoing developments surrounding Hims & Hers Health, Inc. warrant close attention, especially for investors with significant losses. Being proactive and engaging legal assistance could be instrumental in navigating this tumultuous situation. Keep an eye on updates from both Hims & Hers and Pomerantz LLP as the legal landscape continues to evolve. For further inquiries or to review the complaint documentation, visit Pomerantz Law Firm's official website.